(7) conducted a cohort study in 52 patients with SARS-CoV-2 in which a positive correlation between the viral load and IgG antibody levels was found


(7) conducted a cohort study in 52 patients with SARS-CoV-2 in which a positive correlation between the viral load and IgG antibody levels was found. The results of this study allowed for the identification of a situation that could be different with regard to the behaviour of the pandemic within the context of exclusively paediatric hospitals. study carried out in a Paediatric Hospital in Mexico City included patients under 18 years of age and health personnel with positive RT-PCR for COVID-19 comparing antibody expression. The development of specific IgG antibodies was measured, the presence of comorbidities, duration, and severity of symptoms was determined. Results: Etoricoxib Sixty-one subjects (20 18 years and Etoricoxib 41 18 years) were analysed. The median sample collection was 3 weeks. There were no differences in the expression of specific antibodies; no differences were shown according to the symptoms’ severity. A positive correlation (= 0.77) was demonstrated between the duration of symptoms and antibody levels. Conclusions: In conclusion, there is a clear association between the duration of the symptoms associated with SARS-CoV-2 infection and the IgG units generated in paediatric and adult patients convalescing from COVID-19. value 0.05. The simple linear regression analysis shows that the weeks of duration of the disease from the appearance of the first symptom in both groups accounts for 70% of the specific expression of IgG (= 0.05) and severe manifestations due to COVID-19 (32 vs. 25%, not significant). The clinical variables did not show differences between age groups. It should be noted that the paediatric population included in this study was recruited from a paediatric hospital centre that mainly cares for children with serious illnesses. This is reflected in the comparison by groups of age, in which 60% of patients were hospitalised, 40% of which were patients also suffering from cancer and undergoing treatment. The duration of symptoms was directly correlated with the expression of antibodies. This is consistent with a study by Gozalbo-Roviro et al. (8) in 32 patients reporting that the expression of antibodies was mainly associated with the temporality of the infection, regardless of whether the subjects required intensive care. Additionally, 64% of the subjects who did not express antibodies at the time of diagnosis were asymptomatic. Jiang et al. analysed a cohort of 214 infected subjects in order to evaluate seroconversion; the data show a median of 7 days (5C8) in the asymptomatic group (85% expressed specific IgG antibodies) compared to 24 (18C29) days (93% expressed IgG) in symptomatic patients (9). Symptoms have shown a poor relationship with the expression of antibodies, Cervia et al. (10) reported in 64 adult patients infected by SARS Cov-2 a positive correlation of specific IgG values with the severity of the disease (pneumonia, need for hospitalisation), days of symptoms and age. In our study, the median time between the result of the PCR and the antibody test was 23 days. In view of these findings, the proportion of subjects without IgG expression may be explained by the time interval in which the antibodies were obtained as well as by the presence of symptomatology. The occurrence of the disease due to COVID-19 is different in the paediatric and adult populations, conditioning factors of which, include the different expression sites of angiotensin-converting enzyme 2 (ACE2) in children (11). Consequently, there is a greater proportion of gastrointestinal or diffuse symptoms, a situation that makes the early identification of the disease by caregivers as well as its timely registration particularly difficult. In Mexico, the BCG vaccine is included in the national vaccination scheme; in this study, in patients older Etoricoxib than 18 years, this history was proportionally higher (100 vs. 60%). During the first global wave of COVID-19 infections, a more severe and lethal behaviour was demonstrated in countries with a vaccination plan without including BCG compared to those with a positive history (12). One of Slc4a1 the hypotheses regarding the effect of this vaccine suggests that there is an epigenetic reprogramming of monocytes to induce a pro-inflammatory response (production of cytokines iL-1, TNF, and IL-6) in subsequent exposures to various viruses, achieving attenuation on the Etoricoxib severity of the disease (13). In this work, this variable was not the primary objective; however, the need for hospitalisation in those over 18 years of age was statistically lower, but the history of the vaccine did not show a Etoricoxib relationship with the expression of specific IgG antibodies for SARS Cov-2. In addition, the greatest comorbidity in the paediatric group was haematologic cancer, in which the therapeutic target is the reduction of immature lymphocytes and which in healthy subjects are responsible for the generation of antibodies (14, 15). It is important to consider that the study subjects were recruited within the setting of a.